Australian government debt

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

Thursday, October 14, 2021 - 6:45am

- Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.

Key Points: 
  • - Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.
  • The company said: "Topelia proposes to offer the ATT treatment alongside the current vaccination program to treat and vaccinate our way out of this pandemic.
  • The novel Antiviral Triple Therapy, to be branded as Ziverdox, comprises TGA-approved medications prescribed for decades with exceptional safety profiles.
  • Topelia Australia was founded based on the wealth of experience in commercialising the ground-breaking triple therapy cure for peptic ulcers which has saved over 18 thousand lives in Australia alone.

Open Universities Australia Leverages Rimini Street’s Proven Tax, Legal and Regulatory Expertise to Meet New Government Requirements

Tuesday, October 12, 2021 - 5:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211012005177/en/
    Open Universities Australia Leverages Rimini Streets Proven Tax, Legal and Regulatory Expertise to Meet New Government Requirements (Photo: Business Wire)
    In February 2018, the Australian Government unveiled its new student data-reporting regulation.
  • Rimini Streets TLR team undertook the development of the regulatory reporting update, enabling the OUA team to focus on other aspects of the project.
  • Rimini Street had a clear plan, collaborating with us to develop a flexible, configurable solution to meet our compliance requirements.
  • Our tax, legal and regulatory team worked in collaboration with Open Universities Australia to build and deliver this solution on time to meet these government regulations.

Australia Successfully Goes Live With Everbridge Public Warning Platform Countrywide, Representing Official Launch of the Australian Government’s Next-Generation National Population Alerting System

Monday, October 4, 2021 - 10:00pm

Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM) and national Public Warning solutions, today confirmed the Australian Government officially launched its new Emergency Alert population warning system, powered by Everbridge.

Key Points: 
  • Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM) and national Public Warning solutions, today confirmed the Australian Government officially launched its new Emergency Alert population warning system, powered by Everbridge.
  • View the full release here: https://www.businesswire.com/news/home/20211004005968/en/
    Australia Successfully Goes Live With Everbridge Public Warning Platform Countrywide (Graphic: Business Wire)
    All Australian states and territories are now live on Everbridge Public Warning following a comprehensive project deployment period.
  • Everbridge will join Australian Government officials this week to discuss the national alerting system and Public Warning best practices at the Australian Disaster Resilience Conference and at the AFAC21 Virtual Conference & Exhibition .
  • We are honored to support Australia on the advancement of its national warning system, said Steve Foster, Vice President of Australia, New Zealand & Oceania at Everbridge.

DGAP-News: Travelex Issuerco 2 Plc: Completion of £15 million Funding Raise

Monday, October 4, 2021 - 12:09pm

The Additional New Money Notes have the same terms and conditions and ISIN (XS2248458049) as the existing new money notes.

Key Points: 
  • The Additional New Money Notes have the same terms and conditions and ISIN (XS2248458049) as the existing new money notes.
  • I am delighted to announce that the recent capital raise has completed, securing an additional 15 million of funding for the business.
  • The additional issuance of new money notes was fully subscribed by our noteholders/ shareholders; demonstrating their continued support for the business.
  • Overall, the business is in a much more positive place and it is encouraging to see these strides forward.

Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia

Monday, August 23, 2021 - 1:30pm

SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK).

Key Points: 
  • SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK).
  • The TGA had previously granted sotrovimab a provisional determination in April, which provides a mechanism for accelerating the provisional marketing authorization of promising new medicines.
  • George Scangos, Ph.D., chief executive officer of Vir, said:The provisional approval of sotrovimab in Australia marks an important milestone for Vir, as it is the first marketing authorization of our first commercial product.
  • GSK is responsible for the commercial marketing of sotrovimab around the world.

MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

Thursday, August 19, 2021 - 12:00pm

Government grant as part of broader manufacturing sector funding demonstrates the backing of the medical cannabis industry by the Australian federal government and recognition of MediPharm Labs Australias role in this industry.

Key Points: 
  • Government grant as part of broader manufacturing sector funding demonstrates the backing of the medical cannabis industry by the Australian federal government and recognition of MediPharm Labs Australias role in this industry.
  • BARRIE, Ontario, Aug. 19, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (MediPharm Labs or the Company) a pharmaceutical company that specializes in cannabis, is pleased to announce its wholly owned subsidiary MediPharm Labs Australia Pty Ltd (MediPharm Labs Australia) has been awarded $330,000 as part of the Australian Governments $50 million Manufacturing Modernisation Fund.
  • MediPharm Labs Australia has now received the first instalment of this grant.
  • Through the awarding of this grant, the Australian Government has recognised MediPharm Labs as a key player in the Australian cannabis industry and the manufacturing sector.